COMMUNIQUÉS West-GlobeNewswire

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
10/02/2025
BOSTON, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by [...]
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results and Updates 2025 Outlook
10/02/2025
Inspire Reports Year-over-Year Revenue Growth of 25% and Earnings per Share Growth of 135% for the Fourth Quarter 2024 MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire [...]
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
10/02/2025
Revenues of €9.2 million for the full year of 2024 Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million structured financing closed with aggregate gross proceeds of €116 [...]
Inventiva publie ses résultats financiers préliminaires pour l'exercice fiscal 2024¹ et fait le point sur son activité
10/02/2025
Chiffre d'affaires de 9,2 millions d'euros pour l’année 2024 Trésorerie et équivalents de trésorerie à 96,6 millions d’euros au 31 décembre 2024 Levée de la première tranche d'un financement structuré d'un montant [...]
Comprehensive Healthcare Welcomes Addictionologist to Strengthen Substance Use Disorder Care Delivery
10/02/2025
YAKIMA, Wash., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Comprehensive Healthcare recently welcomed its first-ever board-certified addictionologist, Dr. Gillian Zuckerman, as part of the community behavioral health provider’s [...]
Revolo to Present at the 2025 AAAAI / WAO Joint Congress
10/02/2025
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced that it will present two posters on its lead candidate, ‘1104, at the 2025 [...]
Compass Health Announces New Recruitment Initiative Showcasing Career Opportunities and Enhanced Benefits
10/02/2025
EVERETT, Wash., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Compass Health, Northwest Washington’s behavioral healthcare leader, has launched a new recruitment initiative aimed at attracting skilled professionals to its mission- [...]
Press Release: Transparency Notification from Shareholders
10/02/2025
Transparency Notification from Shareholders Ghent, Belgium – 10 February 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of fluid overload in [...]
Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol
10/02/2025
Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025 Monrovia, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ: IZTC) ("Invizyne"), a leading designer of cell-free, [...]
Notification of managers' transactions
10/02/2025
ANNOUNCEMENT NO. 288 10 February 2025 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares [...]
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
10/02/2025
FDA RMAT designation follows positive proof-of-concept U.S. clinical data from the NXC-201 NEXICART-2 clinical trial in relapsed/refractory AL Amyloidosis RMAT designation potentially streamlines the path to market [...]
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting
10/02/2025
WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today [...]
Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response
10/02/2025
The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection. Golden, CO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. ( [...]
SoldierStrong Joins Forces With Patriot Mobile to Assist Military Veterans in Taking Their Next Steps Forward
10/02/2025
STAMFORD, Conn., Feb. 10, 2025 (GLOBE NEWSWIRE) -- SoldierStrong, a national nonprofit dedicated to providing revolutionary medical technology to U.S. Department of Veterans Affairs medical facilities and individual [...]
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
10/02/2025
HOUSTON, TEXAS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces its [...]
Capricor Therapeutics to Participate in Upcoming Investor Conferences
10/02/2025
SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today [...]
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
10/02/2025
Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company advancing Phase 1a/ [...]
BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress
10/02/2025
RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new clinical and real-world outcomes [...]
Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial
10/02/2025
No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial Achieve Reiterates Planned Cytisinicline NDA Submission in Q2 2025 SEATTLE and VANCOUVER, British Columbia, Feb. 10, 2025 (GLOBE NEWSWIRE [...]

Pages